We thank Ziran Qiu and Na Jin for their Correspondence regarding the FABULOUS trial1 and appreciate their practical perspectives.
[Correspondence] Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China – Authors' reply
The Lancet Oncology | | Jieqiong Liu, Yaxin Liu, Erwei Song, Huiping Li
Topics: breast-cancer, cervical-cancer